Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 18, 2022

Standard and Hypofractionated Dose Escalation to Intraprostatic Tumour Nodules in Localised Prostate Cancer

International Journal of Radiation Oncology, Biology, Physics


Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Radiation Oncology, Biology, Physics
Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: 5 year efficacy and toxicity in the DELINEATE trial
Int. J. Radiat. Oncol. Biol. Phys 2022 Sep 20;[EPub Ahead of Print], AC Tree, L Satchwell, E Alexander, I Blasiak-Wal, N deSouza, A Gao, E Greenlay, H McNair, C Parker, J Talbot, D Dearnaley, J Murray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading